Emergent BioSolutions Initiates Phase 1b Study of TRU-016 in Combination with Rituximab

Emergent BioSolutions

announced today the initiation of a Phase 1b study (Protocol 16009) of TRU-016 in combination with rituximab for patients with previously untreated chronic lymphocytic leukemia (CLL). TRU-016 is a humanized anti-CD37 mono-specific protein therapeutic in development for the treatment of B-cell malignancies. “Preclinical studies have shown increased anti-tumor activity for the combination of TRU-016 and rituximab beyond the levels achieved when either drug was administered alone,” said Scott C. Stromatt, M.D., Senior Vice President and Chief Medical Officer, Emergent BioSolutions. “We look forward to clinical evaluation of the effect of TRU-016 in combination with rituximab in previously untreated CLL patients.” The Phase 1b,